** Shares of medical device maker Tivic Health Systems TIVC.O more than double to 49 cents; set to record the largest single-day percentage gain
** TIVC says it has acquired exclusive worldwide rights from Statera Biopharma STAB.PK to a late-stage immunotherapy drug called entolimod, which is used for the treatment of acute radiation syndrome $(ARS.UK)$, a condition caused by exposure to high doses of ionizing radiation
** The deal includes an initial payment of $1.2 million in equity and $300,000 in cash to Statera
** Drug has the potential to be approved by the U.S. FDA within two years - TIVC
** The FDA has granted "fast track" and "orphan drug" designation to entolimod for the treatment of ARS - TIVC
** The global ARS market is estimated to be valued at $5.2 billion in 2024 with a compound annual growth rate of 5% from 2024 to 2031 - TIVC
** TIVC fell 80.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。